
    
      The purpose of this postapproval study is to conduct a prospective, multi-center evaluation
      of the procedural and clinical outcomes of subjects that are treated with the commercially
      available 34 mm and 38 mm Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent
      System.

      Descriptive statistics and 95% confidence intervals will be calculated for clinically
      relevant variables as described in a separate statistical analysis plan.
    
  